Market Report, "Vietnam Pharmaceuticals & Healthcare Report Q4 2015", published

Counterfeit and substandard medicines will remain highly pervasive in Vietnam's pharmaceutical market. While this reflects the limited capacity of regulators to address the problem, its persistence also illustrates the presence of a sizeable market for manufacturers of counterfeit and low quality medicines. We highlight that pharmaceutical products most affected by this practice are small molecule medicines.

Headline Expenditure Projections

Pharmaceuticals: VND80,731bn (USD3.81bn) in 2014 to VND92,719bn (USD4.32bn) in 2015; +14.9% in local currency terms and +13.4% in US dollar terms.
Healthcare: VND234,889bn (USD11.08bn) in 2014 to VND258,648bn (USD12.05bn) in 2015; +10.1% in local currency terms and +8.7% in US dollar terms.

Risk Reward Index

Vietnam's Pharmaceutical Risk Reward Index score for Q315 is 47.9 out of the maximum 100. The country scored above average for some indicators and sub-indicators, including overall market expenditure, sector value growth and pensionable population. Consequently, with this moderate score, Vietnam is ranked 11th out of the 19 key Asia Pacific markets, level with Thailand and Indonesia.

Full Report Details at
- http://www.fastmr.com/prod/1058456_vietnam_pharmaceuticals.aspx?afid=301

Key Trends And Developments

Vietnam has met international vaccine-management standards and is eligible for exporting its domestically produced vaccines, according to World Health Organization (WHO) representative Lahouari Belghabi. The country's National Regulatory Authorities has scored more than 90% in its critical control functions during an assessment carried out by 14 WHO specialists. The functions include surveillance of vaccine performance in the field, regular inspections for good manufacturing practice and evaluation of clinical performance. The country is among 39 countries that meet WHO's strict vaccine standards, and is expected to become one of the world's leading vaccine producers in 20 or 30 years, Belghabi noted (Vietnamnet).

The Vietnam Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Vietnam Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Vietnam pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's pharmaceutical and healthcare market forecasts for Vietnam, to test other views - a key input for successful budgeting and strategic business planning in the Vietnamese pharmaceutical and healthcare market.
* Target business opportunities and risks in the Vietnamese pharmaceutical and healthcare sector

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Bahrain Pharmaceuticals & Healthcare Report Q4 2015
- Romania Pharmaceuticals & Healthcare Report Q4 2015
- Bulgaria Pharmaceuticals & Healthcare Report Q4 2015
- Peru Pharmaceuticals & Healthcare Report Q4 2015
- Latvia Pharmaceuticals & Healthcare Report Q4 2015